Clinical Trials - Multiple Treatments, Multiple End Points, and Multiple Lessons

JAMA

Volumn 289, Issue 19, 2003, Pages 2575-2577

  Lauer, Michael S ^a,b   Topol, Eric J ^a  

^a Dept of Cardiovascular Medicine ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; EDITORIAL; EVIDENCE BASED MEDICINE; MEDICAL RESEARCH; MORTALITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING; VALIDATION PROCESS; CONTROLLED CLINICAL TRIAL; METHODOLOGY; NOTE; RANDOMIZED CONTROLLED TRIAL; STANDARD; STATISTICS;

DATA INTERPRETATION, STATISTICAL; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0037636758     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.19.2575     Document Type: Editorial

References (25)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
2. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289:2554-2559.
3. Gottlieb SS. Dead is dead - artificial definitions are no substitute. Lancet. 1997;349:662-663.
4. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol. 1999;34:618-620.
5. Topol EJ, Califf RM, Van de Werf F, et al, Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group, Perspectives on large-scale cardiovascular clinical trials for the new millennium. Circulation. 1997;95:1072-1082.
6. Lloyd-Jones DM, Martin DO, Larson MG, Levy D. Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med. 1998;129:1020-1026.
7. Cairns JA, Connolly SJ, Roberts R, Gent M, Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet. 1997;349:675-682.
8. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/ IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
9. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331:394-398.
10. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein Ilb/IlIa blockade compared with heparin and planned glycoprotein Ilb/ IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA, 2003;289:853-863,
11. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
12. Holmvang L, Hasbak P, Clemmensen P, Wagner G, Grande P. Differences between local investigator and core laboratory interpretation of the admission electrocardiogram in patients with unstable angina pectoris or non-Q-wave myocardial infarction (a Thrombin Inhibition in Myocardial Ischemia [TRIM] substudy). Am J Cardiol. 1998;82:54-60.
13. Mahaffey KW, Harrington RA, Akkerhuis M, et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med. 2001;2:187-194.
14. Mahaffey KW, Roe MT, Dyke CK, et al, Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J. 2002;143:242-248.
15. Naslund U, Grip L, Fischer-Hansen J, Gundersen T, Lehto S, Wallentin L. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. Eur Heart J. 1999;20:771-777.
16. Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA. 2003;289:1117-1123.
17. Cole BF, Gelber RD, Anderson KM, International Breast Cancer Study Group. Parametric approaches to quality-adjusted survival analysis. Biometrics. 1994;50:621-631.
18. Shen Y, Thall PF. Parametric likelihoods for multiple non-fatal competing risks and death. Stat Med. 1998;17:999-1015.
19. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA. 2003;289:2545-2553.
20. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
21. Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med. 2000;109:371-377.
22. Rennie D. CONSORT revised-improving the reporting of randomized trials. JAMA. 2001;285:2006-2007.
23. Rennie D. How to report randomized controlled trials: the CONSORT statement. JAMA. 1996;276:649.
24. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708-713.
25. Lauer MS. Primary angioplasty-time is of the essence. JAMA. 2000;283:2988-2989.